(Press-News.org) PORTLAND, Ore. - The number of attention deficit hyperactivity disorder (ADHD) cases in the United States are exploding. According to a 2011 statement by the Centers for Disease Control and Prevention, nearly one in 10 American children is diagnosed with the disorder. To better understand the cause of ADHD and to identify methods to prevent and treat it, researchers at Oregon Health & Science University (OHSU) and OHSU's Oregon National Primate Research Center have developed a new form of specially bred mouse that mimics the condition. The research is published in the current edition of the PLoS ONE, a journal of the Public Library of Science.
The research, led by OHSU and ONPRC scientists Jacob Raber, Ph.D., and Sergio Ojeda, D.V.M., found that mice carrying a certain mutated form of gene displayed the human-like symptoms of ADHD. The scientists believe that mice bred with this unique genome can greatly assist in research to combat ADHD.
The specific gene that was studied in this research is called SynCAM1, which is found in glial cells — a type of cell in the central nervous system involved in cellular communication. The researchers found that mice carrying a dominant/negative form of the gene were hyperactive. The mice displayed enhanced and more frequent activity during rest periods. In addition, the mice exhibited reduced anxiety, similar to children diagnosed with ADHD. The mutated gene caused these conditions because it blocks the actions of the normal gene.
"While some animal models for ADHD exist, they are far from perfect," explained Raber, a professor of behavioral neuroscience and neurology in the OHSU School of Medicine and an affiliate scientist at ONPRC "For instance, a rat model of this condition displays high blood pressure also known as spontaneous hypertensive rats or SHR, which is not observed in humans with ADHD. When hypertension is eliminated by crossing SHR rats to another commonly studied rat breed, the resulting rat has normal blood pressure but no longer responds to the methylphenidate in a way that humans with ADHD do."
"We believe that this animal model may more closely mimic ADHD and shed new light on this condition," added Ojeda, a senior scientist at ONPRC.
###The ONPRC, National Institutes of Health and the National Alliance for Research on Schizophrenia and Depression funded this research.
About OHSU (www.ohsu.edu)
Oregon Health & Science University is the state's only academic health and research university. As Portland's largest employer with nearly 14,000 employees, OHSU's size contributes to its ability to provide many services and community support not found anywhere else in the state. OHSU serves patients from every corner of Oregon and is a conduit for learning for more than 4,300 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to each county in the state.
OHSU researchers develop new animal model for 1 of the least understood medical issues: ADHD
2012-05-11
ELSE PRESS RELEASES FROM THIS DATE:
Long-term use of osteoporosis medication may reduce bone fracture risk for some patients
2012-05-11
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it. Based on available evidence, a UCSF researcher reevaluated his 2006 finding from a randomized 10-year study of alendronate, a type of bisphosphonate – a class of drugs that prevent loss of bone mass.
"Our study suggests that even after five years of therapy, if your bone density is low enough, you're at high risk for having additional spine fractures," said Dennis Black, ...
Safer sex work spaces reduce violence and HIV risks for street-involved women
2012-05-11
Safer indoor sex work spaces provide important and potentially life-saving benefits to sex workers including reduced exposure to violence and HIV and improved relationships with police, according to a study published by the Gender and Sexual Health Initiative of the BC Centre for Excellence in HIV/AIDS (BC-CfE) and the University of British Columbia (UBC).
The qualitative evaluation study published today in the America Journal of Public Health interviewed 39 women living in low-threshold, supportive housing programs for sex workers in poverty and using drugs. These programs, ...
ASBMR responds to NEJM's study on biphosphonates
2012-05-11
WASHINGTON, May 9, 2012 – The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment. Bisphosphonates are a widely prescribed class of drugs that are proven to be effective in reducing common bone fractures in people with osteoporosis and at high risk of fractures. Bisphosphonates include the drugs Aclasta, Actonel, Aredia, Bondronat, Boniva, Didronel, Fosamax, ...
Scientists discover new site of potential instability in West Antarctic Ice Sheet
2012-05-11
Using ice-penetrating radar instruments flown on aircraft, a team of scientists from the U.S. and U.K. have uncovered a previously unknown sub-glacial basin nearly the size of New Jersey beneath the West Antarctic Ice Sheet (WAIS) near the Weddell Sea. The location, shape and texture of the mile-deep basin suggest that this region of the ice sheet is at a greater risk of collapse than previously thought.
Team members at The University of Texas at Austin compared data about the newly discovered basin to data they previously collected from other parts of the WAIS that also ...
Response to first drug treatment may signal likelihood of future seizures in people with epilepsy
2012-05-11
In a study published in Neurology®, the medical journal of the American Academy of Neurology, Professor Kwan, who is also head of the clinical epilepsy program at the Royal Melbourne Hospital and an international authority in antiepileptic drug development, believes a pattern emerges in the early stages.
"Our research shows a pattern based on how a person responds to initial treatment and specifically, to their first two courses of drug treatment," said Dr Kwan.
For the study, 1,098 people from Scotland between the ages of nine and 93 with newly diagnosed epilepsy ...
NTU scientists invent superbug killers
2012-05-11
The superbugs have met their match.
Conceived at Nanyang Technological University (NTU), it comes in the form of a coating which has a magnetic-like feature that attracts bacteria and kills them without the need for antibiotics.
The killer coating, which has shown to destroy 99 per cent of the bacteria and fungi that it comes in contact with, is now being used by two companies: a contact lens manufacturer and a company specialising in animal care products.
The next step is to extend its use in a wide range of biomedical and consumer products, ranging from implants ...
Researchers identify genetic mutation causing rare form of spinal muscular atrophy
2012-05-11
LOS ANGELES (May 9, 2012) – Scientists have confirmed that mutations of a gene are responsible for some cases of a rare, inherited disease that causes progressive muscle degeneration and weakness: spinal muscular atrophy with lower extremity predominance, also known as SMA-LED.
"Typical spinal muscular atrophies begin in infancy or early childhood and are fatal, involving all motor neurons, but SMA-LED predominantly affects nerve cells controlling muscles of the legs. It is not fatal and the prognosis is good, although patients usually are moderately disabled and require ...
Autumn warning: Cancer-causing skin damage is done when young
2012-05-11
With high UV levels continuing in Queensland this autumn, young people are at risk of suffering the worst skin damage they will receive during their lifetime, research from Queensland University of Technology (QUT) has found.
Researcher Professor Michael Kimlin from QUT's AusSun Research Lab said the study found UV exposure during a person's first 18 years of life was the most critical for cancer-causing skin damage and skin aging.
Professor Kimlin said while people aged over 50 had the slowest rate of skin degradation, results indicated that damage still occurred even ...
Immune drug doesn't help kids with hard-to-treat kidney disorder
2012-05-11
Highlights
Children with a particular kidney immune disorder that is unresponsive to standard treatments do not benefit from the immune drug rituximab.
Additional studies are needed to fully understand the disease and to develop effective therapies for hard-to-treat cases.
Washington, DC (May 10, 2012) — The drug rituximab, an antibody that targets the immune system and is often used to treat immune disorders such as lymphoma and arthritis, has recently emerged as a potential treatment for a childhood kidney disorder known as idiopathic nephrotic syndrome (INS). While ...
Researchers discover that obesity hinders kidney donation
2012-05-11
Researchers at the Hofstra North Shore-LIJ School of Medicine and Feinstein Institute for Medical Research conducted a retrospective analysis which found that morbid obesity impedes kidney donation. In fact, in the analysis of 104 potential living kidney donors, 23 (22 percent) donors were classified as morbidly obese, only three (13 percent) of whom were able to successfully lose weight and donate their kidney. This data will be presented at the National Kidney Foundation (NKF) 2012 Spring Clinical Meetings, to be held from May 9-13 in Washington, DC.
Morbidly obese ...